CYP2D6 gene as a biomarker for predicting the dose of ondansetron for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy
Not Applicable
- Conditions
- Health Condition 1: K800- Calculus of gallbladder with acutecholecystitis
- Registration Number
- CTRI/2021/08/035812
- Lead Sponsor
- niversity College of Medical Sciences and GTB Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with ASA physical status I or II undergoing laparoscopic cholecystectomy under GA.
Exclusion Criteria
Pregnant patients; BMI > 35 kg/m²; Patients having history of significant cardiac, hepatic or renal disease; Patients having nausea or vomiting 24 hours before surgery and/or those receiving any other antiemetics within last 24 hours; Patients on any potential CYP2D6 inhibitors for e.g., beta-adrenergic blocking agents, TCAs, antiarrhythmic 1c class drugs, debrisoquine, codeine or dextromethorphan; & patients with known hypersensitivity to 5HT3 agents.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method correlation between the specific allele of CYP2D6 between responders and non-respondersTimepoint: baseline sample before surgery
- Secondary Outcome Measures
Name Time Method To compare the total rescue analgesic consumption between the responders and non-responders in 24 hours & <br/ ><br>The total rescue antiemetic consumption in 24 hours in non-respondersTimepoint: From the blood sample taken at the baseline for gene polymorphism study